Aquila Diagnostic Systems Inc. Raises $1.75 Million Investment in Series A Financing
June 16, 2016 - Aquila Diagnostic Systems Inc., announces the closing of a $1.75 million Series A financing round with Benslie International Ltd.
Aquila Diagnostic Systems Inc. is a privately held Canadian company commercializing its innovative Accutas solution for a point-of-care molecular (DNA/RNA) diagnostic testing system. The patented Accutas solution provides low cost, laboratory quality diagnostics at the point-of-care, eliminating cost and inconvenience of waiting days or weeks for laboratory results to be returned and the subsequent follow-up visit or treatment. Aquila is preparing to enter large markets for the companion animal and food production sectors.
“This new technology... opens up the possibility of using a simple and highly sensitive molecular test at the point-of-care for the diagnosis of malaria and other blood-borne infections.”
Chief Scientific Officer Mark Perkins, Foundation for Innovative New Diagnostics (FIND), Geneva, in a favourable assessment showing Aquila’s Accutas™ diagnostic system achieved results superior to current malaria testing systems.